Chang EWY, Tan YH, Chan JY. Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma. J Hematol Oncol. 2024. https://doi.org/10.1186/s13045-024-01560-7.

Article  PubMed  PubMed Central  Google Scholar 

Bellei M, Foss FM, Shustov AR, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica. 2018;103(7):1191–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang H, Zhang W, Deng X, et al. Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting. Exp Hematol Oncol. 2024. https://doi.org/10.1186/s40164-024-00510-w.

Article  PubMed  PubMed Central  Google Scholar 

Su Q, Banks E, Bebernitz G, et al. Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a potent and selective Janus kinase 1 inhibitor. J Med Chem. 2020;63(9):4517–27.

Article  CAS  PubMed  Google Scholar 

Moskowitz AJ, Ghione P, Jacobsen E, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brooks AJ, Putoczki T. JAK-STAT signalling pathway in cancer. Cancers (Basel). 2020. https://doi.org/10.3390/cancers12071971.

Article  PubMed  PubMed Central  Google Scholar 

Song Y, Yoon DH, Yang H, et al. Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas. Ann Oncol. 2023;34(11):1055–63.

Article  CAS  PubMed  Google Scholar 

Dizal (Jiangsu) Pharmaceutical Co Ltd. Golidocitinib: Chinese prescribing information. Shanghai: Dizal (Jiangsu) Pharmaceutical Co Ltd; 2024.

Google Scholar 

Dizal (Jiangsu) Pharmaceutical Co Ltd. Pipeline and strategy. 2023. https://dizalpharma.com/innovation/P&S. Accessed 12 Aug 2024.

Dizal (Jiangsu) Pharmaceutical Co Ltd. Golidocitinib approved in China as first-in-class JAK1 only inhibitor for the treatment of relapsed or refractory peripheral T-cell lymphoma [media release]. 19 June 2024. https://www.dizalpharma.com/.

AstraZeneca. AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China [media release]. 27 Nov 2017. https://www.astrazeneca.com.

Ye Y, Wu M, Mi L, et al. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Janus kinase 1 (JAK1) inhibitor AZD4205 on Peripheral T cell lymphoma [abstract no. 418]. Hematol Oncol. 2023;41(S2):558–9.

Article  Google Scholar 

Chen K, Guan X, Yang Z, et al. Pharmacokinetic characteristics of golidocitinib, a highly selective JAK1 inhibitor, in healthy adult participants. Front Immunol. 2023. https://doi.org/10.3389/fimmu.2023.1127935.

Article  PubMed  PubMed Central  Google Scholar 

Song Y, Malpica L, Cai Q, et al. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study. Lancet Oncol. 2024;25(1):117–25.

Article  CAS  PubMed  Google Scholar 

Jin J, Cai QQ, Zhang LL, et al. Phase 2 study of golidocitinib, a JAK1 selective inhibitor, as maintenance therapy in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26) [abstract no. 4430 plus poster]. Blood. 2023;142(Suppl 1):4430–2.

Article  Google Scholar